Comment
doi: 10.1002/ejhf.2466.
Epub 2022 Mar 9.
Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'
Affiliations
- PMID: 35238461
- DOI: 10.1002/ejhf.2466
Item in Clipboard
Comment
Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'
Eur J Heart Fail.
2022 Jul.
Free article
No abstract available
Comment on
-
Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial.Eur J Heart Fail. 2022 Feb;24(2):245-248. doi: 10.1002/ejhf.2420. Epub 2022 Jan 18. Eur J Heart Fail. 2022. PMID: 34989083 No abstract available.
Similar articles
-
Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.Int J Med Sci. 2022 Jun 21;19(7):1118-1121. doi: 10.7150/ijms.72772. eCollection 2022. Int J Med Sci. 2022. PMID: 35919809 Free PMC article. Review.
-
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16. Eur J Heart Fail. 2019. PMID: 31523904
-
A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'.Eur J Heart Fail. 2021 May;23(5):841. doi: 10.1002/ejhf.2091. Epub 2021 Feb 4. Eur J Heart Fail. 2021. PMID: 33377246 No abstract available.
-
Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction: Proposed Mechanisms, Recent Evidence, and Clinical Implications.Cardiol Rev. 2024 May-Jun 01;32(3):263-266. doi: 10.1097/CRD.0000000000000501. Epub 2022 Dec 28. Cardiol Rev. 2024. PMID: 36728757
-
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.Heart Fail Clin. 2022 Oct;18(4):579-586. doi: 10.1016/j.hfc.2022.03.010. Heart Fail Clin. 2022. PMID: 36216487 Review.
Cited by
-
Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.Int J Med Sci. 2022 Jun 21;19(7):1118-1121. doi: 10.7150/ijms.72772. eCollection 2022. Int J Med Sci. 2022. PMID: 35919809 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
